The global need for new antimalarial drugs and new combinations is enormous and urgent, but their successful delivery needs resilience to overcome the barriers imposed by expensive and lengthy clinical development plans. Adequate assessment of antimalarial drugs should not be restricted to investigating their ability to cure a single infection safely, but to rather account for their overall efficacy in decreasing the long-term cumulative incidence of disease and their prolonged safety when used repeatedly. 

Bassat, Quique, and Sangeev Krishna, “Widening the Options for Recurrent Malaria,” The Lancet 391, no.10128 (March 2018), doi:10.1016/S0140-6736(18)30630-5

URL: www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30630-5/fulltext